Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Copy number alteration of the interferon gene cluster in cancer: Individual patient data meta-analysis prospects to personalized immunotherapy.
Neoplasia
September 2021
Department of Biosciences and Nutrition, Neo, Karolinska Institute, Huddinge, Sweden. Electronic address:
Interferon (IFN) therapy has been the standard of care for a variety of cancers for decades due to the pleiotropic actions of IFNs against malignancies. However, little is known about the role of copy number alteration (CNA) of the IFN gene cluster, located at the 9p21.3, in cancer.
View Article and Find Full Text PDFAdjuvant therapy with low-dose interferon-beta for stage II and III melanoma: results of a retrospective analysis.
Clin Exp Dermatol
October 2017
Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Interferon (IFN)-alfa as an adjuvant therapy has been found to improve relapse-free survival in patients with malignant melanoma (MM). However, the efficacy of IFN-beta has not been studied in detail. This study evaluated the contribution of adjuvant IFN-beta therapy to improvements in the prognosis of patients with MM.
View Article and Find Full Text PDFA case of septal panniculitis secondary to interferon treatment.
Cutan Ocul Toxicol
December 2014
Department of Dermatology and.
The most common side effects of interferon-beta therapy following subcutaneous administration include pain, inflammation and induration at the injection site, which occur in approximately 20-60% of patients. Besides, transient injection-site erythema is frequently seen in beta-interferon therapy. Less frequent reactions at injection sites include vascular thrombosis, mucinosis, dermal and systemic sclerosis, necrosis, and ulceration.
View Article and Find Full Text PDFEvaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report.
Neurol Neurochir Pol
August 2013
Klinika Neurologiczna, 10 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ, ul. Powstańców Warszawy 5, 85-681 Bydgoszcz.
Background And Purpose: Oral fingolimod 0.5 mg daily was approved in the European Union in 2011 for the treatment of relapsing multiple sclerosis in the aggressive form and as a second line treatment in patients with high disease activity despite interferon beta therapy. The aim of this study was the evaluation of efficacy, safety and tolerance of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS) during a 12-month observation period.
View Article and Find Full Text PDFEfficacy and safety of beta-interferon in Thai patients with demyelinating diseases.
Mult Scler
April 2013
Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Background: The efficacy of beta-interferon (IFN-β) treatment in Thai patients with demyelinating diseases has not been reported.
Objectives: To evaluate the efficacy and any adverse drug reactions of IFN-β therapy in Thai patients, for each group of demyelinating diseases.
Methods: We retrospectively reviewed data of Thai patients with multiple sclerosis (MS), neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSDs) who attended the MS Clinic at Siriraj Hospital, Thailand from March 2000 to October 2011.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!